Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Myeloid 2Dermatologic 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Mastocytosis, Systemic 1Leukemia, Mast-Cell 1Hematologic Diseases 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 162fludarabine phosphate 127Mycophenolic Acid 96Tacrolimus 92Whole-Body Irradiation 85Busulfan 85Peripheral Blood Stem Cell Transplantation 82fludarabine 79Cyclosporine 68Melphalan 63Antilymphocyte Serum 58Filgrastim 56Methotrexate 55Thiotepa 39Radiotherapy 39Cord Blood Stem Cell Transplantation 34Granulocyte Colony-Stimulating Factor 29Cytarabine 28Methylprednisolone 27Stem Cell Transplantation 26Sirolimus 24thymoglobulin 23Etoposide 23Clofarabine 22Rituximab 19Flow Cytometry 15Cyclosporins 15sargramostim 13Specimen Handling 13Alemtuzumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Precursor Cell Lymphoblastic Leukemia-Lymphoma × Brentuximab Vedotin × Myeloid × Clear all
NCT01700751 2019-04-16

Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation

Washington University School of Medicine

Phase 1 Completed
17 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01461538 2016-03-04

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Seagen Inc.

Phase 2 Completed
84 enrolled 20 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡